Basilea Launches Complementary Phase III Trial For Anti-infective Candidate
This article was originally published in The Pink Sheet Daily
New trial adds to data on isavuconazole for invasive yeast and mold infections.
You may also be interested in...
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.